• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cadrenal Therapeutics Inc.

    2/3/25 5:12:42 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVKD alert in real time by email
    S-8 1 ea0229415-s8_cadrenal.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on February 3, 2025

    Registration No. 333-            

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    CADRENAL THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)  

     

    Delaware   88-0860746

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    822 A1A North, Suite 306

    Ponte Vedra, Florida 32082

    (Address of Principal Executive Offices and Zip Code)

     

    CADRENAL THERAPEUTICS, INC. 2022 SUCCSESOR EQUITY INCENTIVE PLAN

    CADRENAL THERAPEUTICS, INC. 2022 EQUITY INCENTIVE PLAN

    (Full title of the plans)

     

    Quang Pham
    Chief Executive Officer
    Cadrenal Therapeutics, Inc.
    822 A1A North, Suite 306

    Ponte Vedra, Florida 32082
    (904) 300-0701

    (Name, address, and telephone number, including area code, of agent for service)

     

    Please send copies of all communications to:

     

    Leslie Marlow, Esq.

    Blank Rome LLP

    1271 Avenue of the Americas

    New York, New York 10020

    (212) 885-5000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated Filer ☐
    Non-accelerated filer ☒ Smaller Reporting Company ☒
      Emerging Growth Company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    INTRODUCTION

     

    Cadrenal Therapeutics, Inc. (the “Registrant” or the “Company”) filed with the Securities and Exchange Commission (the “Commission”) its Registration Statement on Form S-8 (Registration No. 333-269372) on January 24, 2023 (the “2023 Registration Statement”), pursuant to and in accordance with the requirements of Form S-8 for the purpose of registering under the Securities Act of 1933, as amended (the “Securities Act”), 3,010,000 shares (pre-reverse stock split) (200,666 shares post-reverse stock split) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issuable to employees, officers, directors, consultants and advisors of the Company under the Registrant’s 2022 Successor Equity Incentive Plan (the “2022 Plan”) and the Registrant’s 2022 Equity Incentive Plan, as amended and restated (the “Initial Plan”). Pursuant to General Instruction E to Form S-8, the 2023 Registration Statement is incorporated into this Registration Statement by reference. 

     

    The Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-277838) on March 12, 2024 (the “March 2024 Registration Statement”), pursuant to and in accordance with the requirements of General Instruction E to Form S-8, for the purpose of registering under the Securities Act an additional 694,550 shares (pre-reverse stock split) (46,303 shares post-reverse stock split) of Common Stock that may be issued pursuant to the 2022 Plan pursuant to an “evergreen” provision contained therein, which is equal to 20% of the total number of shares of Common Stock outstanding on December 31, 2023, resulting in a total of 2,604,550 shares (pre-reverse stock split) (173,636 shares post-reverse stock split) of Common Stock available for issuance under the 2022 Plan. Pursuant to General Instruction E to Form S-8, the March 2024 Registration Statement is incorporated into this Registration Statement by reference.

     

    On August 20, 2024, the Registrant effected a one-for-fifteen reverse stock split, which reduced the number of shares reserved under the 2022 Plan to 173,636.

     

    The Registrant also filed with the Commission its Registration Statement on Form S-8 (Registration No. 333-284024) on December 23, 2024 (the “December 2024 Registration Statement”), pursuant to and in accordance with the requirements of General Instruction E to Form S-8, for the purpose of registering under the Securities Act an additional 133,333 shares (post-reverse stock split) of the Common Stock that may be issued pursuant to the 2022 Plan, pursuant to an amendment to the 2022 Plan to increase the number of shares of Common Stock available for awards under the 2022 Plan by 133,333 (post-reverse stock split) shares of Common Stock to 306,969 (post-reverse stock split) shares of Common Stock, which amendment was approved by the Company’s Board of Directors on May 25, 2024 and the Company’s stockholders at its 2024 Annual Meeting of Stockholders held on July 29, 2024. Pursuant to General Instruction E to Form S-8, the December 2024 Registration Statement is incorporated into this Registration Statement by reference.

     

    Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement on Form S-8 (the “Registration Statement”) for the purpose of registering under the Securities Act an additional 172,716 shares of Common Stock that may be issued pursuant to the Registrant’s 2022 Successor Equity Incentive Plan (the “2022 Plan”) pursuant to an “evergreen” provision contained therein, resulting in a total of 479,685 shares of Common Stock available for issuance under the 2022 Plan, which is equal to 20% of 2,398,426, the aggregate of: (i) the shares of Common Stock outstanding on December 31, 2024, and (ii) the shares of Common Stock issuable upon exercise of warrants and pre-funded warrants outstanding on December 31, 2024.

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information*

     

    Item 2. Registrant Information and Employee Plan Annual Information*

     

    *The information specified in Item 1 and Item 2 of Part I of this Registration Statement on Form S-8 is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants in the Plan as required by Rule 428. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The Securities and Exchange Commission (the “Commission”) allows us to “incorporate by reference” the information we file with it which means that we can disclose important information to you by referring you to those documents instead of having to repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and later information that we file with the Commission will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings made with the Commission under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), between the date of this prospectus and the termination of the offering:

     

    ●The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 (Commission File No. 001-41596) filed with the Commission on March 11, 2024;

     

    ●The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (Commission File No. 001-41596) filed with the Commission on May 9, 2024;

     

    ●The Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (Commission File No. 001-41596) filed with the Commission on August 7, 2024;

     

    ●The Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (Commission File No. 001-41596) filed with the Commission on November 7, 2024;

     

    ●The Registrant’s Current Reports on Form 8-K filed with the Commission on February 12, 2024, March 5, 2024, March 12, 2024, April 9, 2024 (other than information furnished under Item 7.01 and exhibits related thereto), May 9, 2024, July 31, 2024, August 6, 2024 (other than information furnished under Item 7.01 and exhibits related thereto), August 16, 2024, August 20, 2024, September 5, 2024, September 25, 2024 (other than information furnished under Item 7.01 and exhibits related thereto), October 24, 2024 (other than information furnished under Item 7.01 and exhibits related thereto) and November 4, 2024;

     

    ●Our Current Report on Form 8-K/A filed with the SEC on February 15, 2024; and

     

    ●The description of our common stock is set forth in our registration statement on Form 8-A filed with the SEC on January 17, 2023, as updated by the description of our common stock filed as Exhibit 4.11 to our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 30, 2023, including any amendments or reports filed for the purpose of updating such description.

     

    All other reports and documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) shall be deemed to be incorporated by reference in this Registration Statement and to be a part of this Registration Statement from the respective date of filing of each of those reports or documents until the filing of a post-effective amendment to this Registration Statement which indicates either that all securities offered by this Registration Statement have been sold or which deregisters all of the securities under this Registration Statement then remaining unsold.

     

    Any statement contained in this Registration Statement or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement modifies or supersedes that statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    II-1

     

     

    PART II

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit   Description
    4.1   Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant’s Registration Statement on Form S-1, filed on December 6, 2022, File No. 333-267562)
    4.2   Amended and Restated Bylaws of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.2 to the registrant’s Registration Statement on Form S-1, filed on December 6, 2022, File No. 333-267562)
    4.3   Certificate of Amendment of Amended and Restated Certificate of Incorporation of Cadrenal Therapeutics, Inc. (Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K, filed on August 20, 2024, File No. 001-41596)
    5.1*   Opinion of Blank Rome LLP
    23.1*   Consent of WithumSmith + Brown, PC, Independent Registered Public Accounting Firm
    23.2*   Consent of Blank Rome LLP (contained in Exhibit 5.1)
    24.1*   Power of Attorney (included on signature page hereto)
    99.1   Cadrenal Therapeutics, Inc. 2022 Equity Incentive Plan and form of Incentive Stock Option Agreement, Non-Qualified Stock Option Agreement for Officers and Other Employees, Non-Qualified Stock Option Agreement for Directors and Consultants, Restricted Stock Agreement, and Restricted Stock Unit Agreement (Incorporated by reference to Exhibit 10.1 to the registrant’s Registration Statement on Form S-1, filed on September 22, 2022, File No. 333-267562)
    99.2   Cadrenal Therapeutics, Inc. 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference to Exhibit 10.14 to the registrant’s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
    99.3   Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the 2022 Amended and Restated Equity Incentive Plan (Incorporated by reference to Exhibit 10.15 to the registrant’s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
    99.4   Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.16 to the registrant’s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
    99.5   Form of Stock Option Grant Notice and Stock Option Agreement and Notice of Exercise under the 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.17 to the registrant’s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
    99.6   Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2022 Successor Equity Incentive Plan (Incorporated by reference to Exhibit 10.18 to the registrant’s Registration Statement on Form S-1/A, filed on October 17, 2022, File No. 333-267562)
    99.7   Amendment to the Cadrenal Therapeutics, Inc. 2022 Successor Equity Incentive Plan (Incorporated by reference as Annex C to the Registrant’s Definitive Proxy Statement on Schedule 14A, filed on June 11, 2024, File No. 001-41596)
    107*   Filing Fee Table

     

     

    *Filed herewith.

     

    II-2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ponte Vedra, State of Florida, on this 3rd day of February, 2025.

     

      CADRENAL THERAPEUTICS, INC.
         
      By: /s/ Quang Pham
      Name: Quang Pham
      Title: Chairman of the Board and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Quang Pham and Matthew Szot his true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Cadrenal Therapeutics, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    ***

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

             

    /s/ Quang Pham

    Quang Pham

     

    Chairman of the Board and Chief Executive Officer

    (Principal Executive Officer)

      February 3, 2025
             

    /s/ Matthew Szot

    Matthew Szot

      Chief Financial Officer
    (Principal Accounting and Financial Officer)
      February 3, 2025
             

    /s/ John R. Murphy

    John R. Murphy

      Director   February 3, 2025
             

    /s/ Steven Zelenkofske

    Steven Zelenkofske

      Director   February 3, 2025
             

    /s/ Glynn Wilson

    Glynn Wilson

     

      Director   February 3, 2025

    /s/ Robert Lisicki

      Director   February 3, 2025

    Robert Lisicki

     

    II-3

     

     

     

     

     

     

    Get the next $CVKD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVKD

    DatePrice TargetRatingAnalyst
    12/18/2023$4.00Outperform
    Noble Capital Markets
    More analyst ratings

    $CVKD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

      Leadership appointment strengthens strategic and development capabilities FDA Type D Meeting provides additional guidance for advancing the clinical development of tecarfarin Collaboration Agreement with Abbott (NYSE:ABT) validates the need for new anticoagulation options Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing therapeutics for patients with cardiovascular disease, today reported its financial results for the first quarter ended March 31, 2025, and provided an update on the strategic focus of the company and clinical development of tecarfarin. "In the first quarter of 2025, Cadrenal continued to build on the momentum we achieved during 2024," sa

      5/8/25 8:00:00 AM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

      Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced that Chairman and CEO Quang X. Pham will present at the inaugural Centri Capital Conference, to be held at Nasdaq in New York City on April 22, 2025. Mr. Pham will deliver a company overview and provide updates on the development of tecarfarin, Cadrenal's lead asset, addressing unmet needs in anticoagulation therapy. The Centri Capital Conference will feature attendees from across the capital markets and investment community, connecting with executives from companies shaping the future of he

      4/17/25 9:40:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

      Management Available for One-to-One Meetings Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company's commitment to advancing innovation and clinical development in anticoagulation therapy. Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18th National Conference on Anticoagulation Therapy in Washington, D.C. from April 3-5, engaging with leading experts and ke

      4/3/25 8:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Cadrenal Therapeutics with a new price target

      Noble Capital Markets initiated coverage of Cadrenal Therapeutics with a rating of Outperform and set a new price target of $4.00

      12/18/23 8:12:12 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Financials

    Live finance-specific insights

    See more
    • Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

      Recent Collaboration Agreement with Abbott Global Enterprises Limited ("Abbott") in support of Phase 3 randomized, multicenter study, entitled TECH-LVAD Recent FDA Type D Meeting provides additional guidance for advancing clinical development of tecarfarin Leadership appointments to strengthen development capabilities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company focused on the development of tecarfarin, a new Phase 3 ready oral vitamin K antagonist, today reported full year results for the period ended December 31, 2024, and provided a business update and highlights of the path forward for the clinical advancement of tecarfarin. "2024 for Cadrenal was a year of

      3/13/25 4:05:00 PM ET
      $ABT
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by CEO and Chairman Pham Quang X

      4/A - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      3/24/25 8:38:14 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Ferguson James J. Iii

      4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      2/6/25 4:51:35 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Ferguson James J. Iii

      3 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

      2/6/25 4:50:29 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Leadership Updates

    Live Leadership Updates

    See more
    • Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

      James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development opportunities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K antagonist, today announced a leadership transition appointing James J. Ferguson, MD, FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson is a distinguished medical expert with over 25

      2/6/25 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

      Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. Quang X. Pham, Chairman and Chief

      12/18/24 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

      PONTE VEDRA, Fla., Feb. 8, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the appointment of Jeff Cole to the newly created position of Chief Operating Officer. In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin. Mr. Cole brings over 25 years of

      2/8/24 9:00:00 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    SEC Filings

    See more
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 4:05:33 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cadrenal Therapeutics Inc.

      10-Q - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      5/8/25 6:17:43 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cadrenal Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

      4/17/25 6:12:02 AM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cadrenal Therapeutics Inc.

      SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

      11/14/24 4:00:17 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cadrenal Therapeutics Inc.

      SC 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

      10/4/24 4:15:02 PM ET
      $CVKD
      Biotechnology: Pharmaceutical Preparations
      Health Care